Masimo is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors.

 
 
  • Oxygen Reserve Index (ORi™)
  • A noninvasive and continuous parameter that provides insight into a patient’s oxygen reserve
 
  • rainbow® Pulse CO-Oximetry
  • The Masimo rainbow SET™ platform has the unique ability to measure dyshemoglobins and total hemoglobin concentration.
 
 
  • CCHD Screening
  • Reliable, Accurate Screening for Critical Congenital Heart Disease (CCHD) with Masimo SET®

News & Media

 
  • August 13, 2018
  • Southampton, United Kingdom
  • Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers investigated whether home pulse oximetry monitoring might be a useful initial screening method of determining which children with down syndrome (DS) […]
  • July 27, 2018
  • Lebanon, New Hampshire
  • Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Dartmouth-Hitchcock Medical Center investigated the impact of an integrated clinical monitoring system, using various Masimo technologies and dev […]
  • July 16, 2018
  • IIzmit, Turkey
  • Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Kocaeli University in Turkey compared the performance of conventional fluid management (CFM) to goal-directed fluid management (GDFM) using Masim […]
  • March 2, 2018
  • Masimo Personal Health
  • MightySat is for people who want to improve their health, wellness, or fitness by providing key measurements that are more accurate & not available on other health and wellness devices. […]
  • February 23, 2018
  • Patient Safety Movement
  • The Patient Safety Movement Foundation believes reaching ZERO preventable deaths in hospitals by 2020 (0X2020™) is not only the right goal, but an attainable one with the […]
  • June 4, 2018
  • 2017 Masimo Annual Report
  • 2017 Masimo Annual Report - Automating Care. Reflecting on the Past and Defining the Future. […]

Next Generation SedLine is not licensed for sale in Canada.

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, and precautions.

Improve Patient Outcomes and Reduce the Cost of Care.

© 2018 Masimo. All Rights Reserved.